<DOC>
	<DOCNO>NCT01966120</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy BF-200 ALA ( Ameluz ) versus placebo field-directed treatment mild moderate actinic keratosis photodynamic therapy ( PDT ) use BF-RhodoLED lamp .</brief_summary>
	<brief_title>Safety Efficacy Study Field-directed Treatment Actinic Keratosis ( AK ) With Photodynamic Therapy ( PDT )</brief_title>
	<detailed_description>The study perform randomize , multicentre , double-blind , placebo- control , parallel-group , phase III trial BF-200 ALA placebo seven centre Germany . A total 94 patient screen study ; 87 randomize ( 55 patient receive BF-200 ALA , 32 receive placebo ) . Patients receive one PDT . If residual lesion remain 3 month treatment , PDT repeat . Illumination perform PDT lamp BF-RhodoLED .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Males females 18 85 year age ( inclusive ) Presence 4 8 clinically confirm actinic keratosis ( AK ) target lesion mild moderate intensity within 12 field History hypersensitivity 5ALA ingredient BF200 ALA Current treatment immunosuppressive therapy Presence malignant benign tumor skin within treatment area ( eg malignant melanoma , basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) ) within last 4 week Confirmed diagnosis SCC representative lesion screen biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Field-directed Treatment</keyword>
</DOC>